Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.49 per share when it actually produced a loss of $1.44, delivering a surprise of -193.88%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Novavax
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.
Novavax shares have lost about 6.9% since the beginning of the year versus the S&P 500’s gain of 9.3%.
What’s Next for Novavax?
While Novavax has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Novavax: mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.80 on $101.73 million in revenues for the coming quarter and -$0.82 on $863.95 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Sutro Biopharma, Inc. (STRO), is yet to report results for the quarter ended March 2024.
This company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of -21.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Sutro Biopharma, Inc.’s revenues are expected to be $11.57 million, down 8.7% from the year-ago quarter.
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
Sutro Biopharma, Inc. (STRO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
